| Co-Investigator(Kenkyū-buntansha) |
津田 真寿美 北海道大学, 医学研究院, 准教授 (30431307)
高阪 真路 国立研究開発法人国立がん研究センター, 研究所, 分野長 (00627119)
黒川 孝幸 北海道大学, 先端生命科学研究院, 教授 (40451439)
前仲 勝実 北海道大学, 薬学研究院, 教授 (10322752)
|
|---|
| Budget Amount *help |
¥45,110,000 (Direct Cost: ¥34,700,000、Indirect Cost: ¥10,410,000)
Fiscal Year 2023: ¥6,760,000 (Direct Cost: ¥5,200,000、Indirect Cost: ¥1,560,000)
Fiscal Year 2022: ¥7,150,000 (Direct Cost: ¥5,500,000、Indirect Cost: ¥1,650,000)
Fiscal Year 2021: ¥9,230,000 (Direct Cost: ¥7,100,000、Indirect Cost: ¥2,130,000)
Fiscal Year 2020: ¥9,620,000 (Direct Cost: ¥7,400,000、Indirect Cost: ¥2,220,000)
Fiscal Year 2019: ¥12,350,000 (Direct Cost: ¥9,500,000、Indirect Cost: ¥2,850,000)
|
|---|
| Outline of Final Research Achievements |
This study aimed to develop the specific hydrogel to facilitate HARP phenomenon by which cancer stem cells are rapidly created by reprogramming. pNaSS sodium sulfonate gel was found to have a high ability to induce the HARP phenomenon. pNaSS gel, which functions as a cancer stem cell niche distinct from the previous gel, and a master regulator of transcriptional regulation was identified. Novel cancer stem cell markers were detected in single cell RNA sequencing analysis. Drug screening platform was established. For clinical application, NAC therapy-resistant cells of human pancreatic cancer were successfully established. Drug screening yielded compounds targeting several drug-resistant cells. We would like to further link this platform to clinical applications.
|
